Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 518 participants.

Also called NCT05307237

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 518 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05307237
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05307237. Randomized; single masking; primary purpose treatment. Start 2022-04-19 (actual); primary completion 2025-12-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)
Acronym
Cyber GEMS
Intervention (Device)
Dexcom G6 Continous Glucose Monitoring Management
Intervention (Device)
Usual Care - Blinded Continuous Glucose Monitoring Management
Lead sponsor
Scripps Whittier Diabetes Institute (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05307237
Content hash
06b265e444d1c47f4a5263deeecc31140ae8c69d2fbac1912b3a1593fe7b62b5